stoxline Quote Chart Rank Option Currency Glossary
  
Vincerx Pharma, Inc. (VINC)
0.6889  -0.034 (-4.72%)    06-13 16:00
Open: 0.71
High: 0.7199
Volume: 115,437
  
Pre. Close: 0.723
Low: 0.682
Market Cap: 20(M)
Technical analysis
2024-06-13 4:47:04 PM
Short term     
Mid term     
Targets 6-month :  0.9 1-year :  1.01
Resists First :  0.77 Second :  0.87
Pivot price 0.68
Supports First :  0.61 Second :  0.5
MAs MA(5) :  0.71 MA(20) :  0.69
MA(100) :  2.47 MA(250) :  1.57
MACD MACD :  -0.2 Signal :  -0.3
%K %D K(14,3) :  71.7 D(3) :  74.9
RSI RSI(14): 36.9
52-week High :  9.37 Low :  0.61
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ VINC ] has closed below upper band by 49.8%. Bollinger Bands are 94.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 32 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.72 - 0.73 0.73 - 0.73
Low: 0.67 - 0.68 0.68 - 0.68
Close: 0.68 - 0.69 0.69 - 0.7
Company Description

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.

Headline News

Tue, 14 May 2024
Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Fri, 26 Apr 2024
Why Vincerx Pharma (VINC) Stock Is Falling - Vincerx Pharma (NASDAQ:VINC) - Benzinga

Thu, 25 Apr 2024
Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants - GlobeNewswire

Tue, 09 Apr 2024
Vincerx stock drops on data for cancer drug (NASDAQ:VINC) - Seeking Alpha

Tue, 09 Apr 2024
Why Is Vincerx Pharma (VINC) Stock Down 64% Today? - InvestorPlace

Tue, 09 Apr 2024
Why Is Small-Cap Cancer Focused Vincerx Pharma Stock Plummeting On Tuesday? - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 30 (M)
Shares Float 17 (M)
Held by Insiders 19.6 (%)
Held by Institutions 35.7 (%)
Shares Short 1,030 (K)
Shares Short P.Month 800 (K)
Stock Financials
EPS -1.78
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.51
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -68.8 %
Return on Equity (ttm) -136.4 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.45
Qtrly Earnings Growth 0 %
Operating Cash Flow -40 (M)
Levered Free Cash Flow -24 (M)
Stock Valuations
PE Ratio -0.39
PEG Ratio 0
Price to Book value 1.32
Price to Sales 0
Price to Cash Flow -0.51
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android